Clinical Adoption of Personalized Medicine: Opportunities and Challenges

Few issues in health and medicine are of graver significance for today’s patients than the clinical practice gaps slowing the adoption of personalized medicine.

In a study published in 2022, PMC and Diaceutics showed that because of inconsistent testing and treatment practices, personalized medicine strategies to deliver appropriate genetically targeted medicines reached fewer than 40 percent of patients who were diagnosed with advanced non-small cell lung cancer (aNSCLC) in 2019. The findings suggest that even in aNSCLC, a disease state where personalized medicine is relatively well-established, about two-thirds of patients are unknowingly denied therapeutic interventions that could help them live longer, healthier lives. One can only imagine what the picture of clinical adoption looks like in disease states where personalized medicine is less well-established.

That is why the planned discussion at this year’s Annual Personalized Medicine Conference titled “Clinical Adoption of Personalized Medicine: Opportunities and Challenges” is so important.

By convening representatives from leading clinical institutions to reflect on opportunities and challenges related to the clinical adoption of personalized medicine, this conversation promises to help pave the way toward a brighter future for the tens of thousands of patients and families who stand to benefit from the broader utilization of some of the most innovative and impactful tests and treatments on the market today.